Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)
March 13, 2023 06:20 AM EDTUpdated March 14, 09:28 AM
Deals
Pharma

Sanofi to pay $2.9B for Proven­tion Bio and its di­a­betes-de­lay­ing drug Tzield

Drew Armstrong

Executive Editor

Sanofi and Proven­tion Bio have made a $2.9 bil­lion deal for the French drug­mak­er to ac­quire the biotech, which last year won ap­proval for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times